antibodies against bcr abl  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc antibodies against bcr abl
    Antibodies Against Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibodies against bcr abl - by Bioz Stars, 2023-01
    94/100 stars

    Images

    antibodies against bcr abl  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc antibodies against bcr abl
    Antibodies Against Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibodies against bcr abl - by Bioz Stars, 2023-01
    94/100 stars

    Images

    bcr abl 3908  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc bcr abl 3908
    Bcr Abl 3908, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcr abl 3908/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bcr abl 3908 - by Bioz Stars, 2023-01
    94/100 stars

    Images

    anti bcr abl antibody  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc anti bcr abl antibody
    The expression of <t>BCR/ABL</t> protein in CML cells was decreased after Ab@Tf-Cou6-PLGA NPs treatment. a The expression of BCR/ABL and p-BCR/ABL in CML cells after Ab@Tf-Cou6-PLGA NPs treatment was detected by western blot assay. b The expression of p-STAT5, p-ERK and p-CRKL in CML cells was detected by western blot assay
    Anti Bcr Abl Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti bcr abl antibody/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti bcr abl antibody - by Bioz Stars, 2023-01
    94/100 stars

    Images

    1) Product Images from "Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells"

    Article Title: Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

    Journal: Journal of Hematology & Oncology

    doi: 10.1186/s13045-021-01150-x

    The expression of BCR/ABL protein in CML cells was decreased after Ab@Tf-Cou6-PLGA NPs treatment. a The expression of BCR/ABL and p-BCR/ABL in CML cells after Ab@Tf-Cou6-PLGA NPs treatment was detected by western blot assay. b The expression of p-STAT5, p-ERK and p-CRKL in CML cells was detected by western blot assay
    Figure Legend Snippet: The expression of BCR/ABL protein in CML cells was decreased after Ab@Tf-Cou6-PLGA NPs treatment. a The expression of BCR/ABL and p-BCR/ABL in CML cells after Ab@Tf-Cou6-PLGA NPs treatment was detected by western blot assay. b The expression of p-STAT5, p-ERK and p-CRKL in CML cells was detected by western blot assay

    Techniques Used: Expressing, Western Blot

    The role of Trim-Away pathway in Ab@Tf-Cou6-PLGA NPs-mediated BCR/ABL degradation. a Proteasome inhibitor MG132 (100 nM) treatment weakened the BCR/ABL degradation effects of Ab@Tf-Cou6-PLGA NPs in CML cells. b The suppression effect of Ab@Tf-Cou6-PLGA NPs on BCR/ABL was reduced by TRIM21 knockdown. c Immunofluorescence assay was used to analyze the colocalization of BCR/ABL and TRIM21 after Ab@Tf-PLGA NPs treatment. Scale bar, 10 μm. d Co-IP analysis of the interaction of BCR/ABL and TRIM21 with Ab@Tf-Cou6-PLGA NPs treatment. e Co-IP analysis of the interaction of BCR/ABL and TRIM21 without Ab@Tf-Cou6-PLGA NPs treatment
    Figure Legend Snippet: The role of Trim-Away pathway in Ab@Tf-Cou6-PLGA NPs-mediated BCR/ABL degradation. a Proteasome inhibitor MG132 (100 nM) treatment weakened the BCR/ABL degradation effects of Ab@Tf-Cou6-PLGA NPs in CML cells. b The suppression effect of Ab@Tf-Cou6-PLGA NPs on BCR/ABL was reduced by TRIM21 knockdown. c Immunofluorescence assay was used to analyze the colocalization of BCR/ABL and TRIM21 after Ab@Tf-PLGA NPs treatment. Scale bar, 10 μm. d Co-IP analysis of the interaction of BCR/ABL and TRIM21 with Ab@Tf-Cou6-PLGA NPs treatment. e Co-IP analysis of the interaction of BCR/ABL and TRIM21 without Ab@Tf-Cou6-PLGA NPs treatment

    Techniques Used: Immunofluorescence, Co-Immunoprecipitation Assay

    The oncogenesis of CML cells was impaired by Ab@Tf-Cou6-PLGA NPs in vivo. a Treatment schedule for CML mice model. b The maximum WBC counts of mice were recorded. c , d The weights of the liver and spleen of mice were measured. e The percent of CD45 + cells in the bone marrow of mice were detected by FCM. f Cells from bone marrow, liver, and spleen of mice were tested by Wright’s stain. The arrows indicate leukemic cells. Scale bar, 10 μm. g The expression of BCR/ABL was observed by immunofluorescence test. Scale bar, 10 μm. h The survival curves of mice were analyzed by Kaplan–Meier methods. Data are presented as the means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Figure Legend Snippet: The oncogenesis of CML cells was impaired by Ab@Tf-Cou6-PLGA NPs in vivo. a Treatment schedule for CML mice model. b The maximum WBC counts of mice were recorded. c , d The weights of the liver and spleen of mice were measured. e The percent of CD45 + cells in the bone marrow of mice were detected by FCM. f Cells from bone marrow, liver, and spleen of mice were tested by Wright’s stain. The arrows indicate leukemic cells. Scale bar, 10 μm. g The expression of BCR/ABL was observed by immunofluorescence test. Scale bar, 10 μm. h The survival curves of mice were analyzed by Kaplan–Meier methods. Data are presented as the means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Techniques Used: In Vivo, Staining, Expressing, Immunofluorescence

    Schematic diagram of degraded the BCR/ABL oncoprotein by Ab@Tf-Cou6-PLGA NPs. The anti-BCR/ABL antibodies were loaded into nanoparticles, and the transferrin was modified on the surface of Ab@Cou6-PLGA NPs to increase the CML targeting ability. The Ab@Tf-Cou6-PLGA NPs could deliver anti-BCR/ABL antibodies into CML cells. In the acidic environment of the lysosome of CML cells, the Ab@Tf-Cou6-PLGA NPs were degraded and the anti-BCR/ABL antibodies were released. The anti-BCR/ABL antibodies can specifically bind to the BCR/ABL oncoprotein and degrade the BCR/ABL protein via the Trim-Away pathway
    Figure Legend Snippet: Schematic diagram of degraded the BCR/ABL oncoprotein by Ab@Tf-Cou6-PLGA NPs. The anti-BCR/ABL antibodies were loaded into nanoparticles, and the transferrin was modified on the surface of Ab@Cou6-PLGA NPs to increase the CML targeting ability. The Ab@Tf-Cou6-PLGA NPs could deliver anti-BCR/ABL antibodies into CML cells. In the acidic environment of the lysosome of CML cells, the Ab@Tf-Cou6-PLGA NPs were degraded and the anti-BCR/ABL antibodies were released. The anti-BCR/ABL antibodies can specifically bind to the BCR/ABL oncoprotein and degrade the BCR/ABL protein via the Trim-Away pathway

    Techniques Used: Modification

    bcr abl  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc bcr abl
    The combination effects of CPT and <t>Bcr-Abl</t> tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of <t>cleaved</t> <t>caspase-3,</t> caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.
    Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bcr abl - by Bioz Stars, 2023-01
    94/100 stars

    Images

    1) Product Images from "Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia"

    Article Title: Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

    Journal: Pharmaceutical Biology

    doi: 10.1080/13880209.2021.1944224

    The combination effects of CPT and Bcr-Abl tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of cleaved caspase-3, caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.
    Figure Legend Snippet: The combination effects of CPT and Bcr-Abl tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of cleaved caspase-3, caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.

    Techniques Used: MTT Assay, Expressing, Western Blot, Staining

    CPT and imatinib treatment promoted the cleavages of caspase proteins and inhibited the expression levels of Bcr-Abl, p-STAT3 and p-eIF4E in tumour tissues. (A) Western blotting analysis on the expression levels of cleaved caspase-3, caspase-9 and PARP of tumour tissues from different groups. (B) Quantification of the cleaved caspase proteins by Image J. (C) Western blotting analysis on the expression levels of Bcr-Abl, p-STAT3 and p-eIF4E of tumour tissues from each group. (D) Quantification of the of the indicated crucial mediators in CML. The greyscale scans analysis of the western blot images was from three independent experiments and fold changes include the normalisation to β-actin. Data are represented as the mean ± SD. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single imatinib treatment group.
    Figure Legend Snippet: CPT and imatinib treatment promoted the cleavages of caspase proteins and inhibited the expression levels of Bcr-Abl, p-STAT3 and p-eIF4E in tumour tissues. (A) Western blotting analysis on the expression levels of cleaved caspase-3, caspase-9 and PARP of tumour tissues from different groups. (B) Quantification of the cleaved caspase proteins by Image J. (C) Western blotting analysis on the expression levels of Bcr-Abl, p-STAT3 and p-eIF4E of tumour tissues from each group. (D) Quantification of the of the indicated crucial mediators in CML. The greyscale scans analysis of the western blot images was from three independent experiments and fold changes include the normalisation to β-actin. Data are represented as the mean ± SD. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single imatinib treatment group.

    Techniques Used: Expressing, Western Blot

    bcr abl  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc bcr abl
    The effect of ND-09 on hematologic tumor cell proliferation. (A) Chemical structure of ND-09. (B) mRNA level of <t>BCR-ABL</t> in hematologic tumor cells. (C) An MTT assay was used to evaluate the inhibitory effect of ND-09 on K562, JURKAT, and HUT78 cell proliferation. (D) An MTT assay was used to evaluate the inhibitory effect of ND-09 on K562 cell proliferation at different time points. *P<0.05, **P<0.01 compared to the untreated control group.
    Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bcr abl - by Bioz Stars, 2023-01
    94/100 stars

    Images

    1) Product Images from "ND-09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR-ABL signaling"

    Article Title: ND-09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR-ABL signaling

    Journal: Oncology Reports

    doi: 10.3892/or.2021.8087

    The effect of ND-09 on hematologic tumor cell proliferation. (A) Chemical structure of ND-09. (B) mRNA level of BCR-ABL in hematologic tumor cells. (C) An MTT assay was used to evaluate the inhibitory effect of ND-09 on K562, JURKAT, and HUT78 cell proliferation. (D) An MTT assay was used to evaluate the inhibitory effect of ND-09 on K562 cell proliferation at different time points. *P<0.05, **P<0.01 compared to the untreated control group.
    Figure Legend Snippet: The effect of ND-09 on hematologic tumor cell proliferation. (A) Chemical structure of ND-09. (B) mRNA level of BCR-ABL in hematologic tumor cells. (C) An MTT assay was used to evaluate the inhibitory effect of ND-09 on K562, JURKAT, and HUT78 cell proliferation. (D) An MTT assay was used to evaluate the inhibitory effect of ND-09 on K562 cell proliferation at different time points. *P<0.05, **P<0.01 compared to the untreated control group.

    Techniques Used: MTT Assay

    The role of BCR-ABL in the biological activity of ND-09 treatment. (A) BCR-ABL mRNA expression and (B) protein expression in wild-type, BCR-ABL knockdown, and BCR-ABL rescue K562 cells were determined by RT-PCR analysis and western blot analysis, respectively. Cells transfected with a control siRNA construct served as negative controls. Samples are derived from the same experiment, and blots were processed in parallel. (C) An MTT assay was used to evaluate the effect of ND-09 on cell proliferation in wild-type, BCR-ABL knockdown, and BCR-ABL rescue cells. (D) Effect of ND-09 on apoptosis in BCR-ABL-depleted K562 cells. Values represent the average of three independent experiments. Data are presented as mean ± SEM (n=3). *P<0.05, **P<0.01 compared to the untreated control group. (E) The binding mode of ND-09 to BCR-ABL (PDB ID: 1IEP). a, ND-09 in the crystal structure of BCR-ABL with electrostatic coloring; b, Hydrogen bonds are depicted by dashed yellow lines; c, ND-09 in the crystal structure of BCR-ABL with hydrophobic coloring. (F) Effect of ND-09 on BCR-ABL kinase activity. Values represent the average of three independent experiments. Values are presented as mean ± SEM (n=3). (G) Levels of BCR-ABL, p-BCR-ABL, ABL, p-ABL, BCR, and p-BCR in K562 cells treated with ND-09 were examined by western blot analysis. Results were quantified by densitometric analysis of the bands and were normalized to GAPDH (internal control). Samples were derived from the same experiment, and blots were processed in parallel. Values represent the average of three independent experiments. Data are presented as the mean ± SEM (n=3). *P<0.05, **P<0.01 compared to the untreated control group.
    Figure Legend Snippet: The role of BCR-ABL in the biological activity of ND-09 treatment. (A) BCR-ABL mRNA expression and (B) protein expression in wild-type, BCR-ABL knockdown, and BCR-ABL rescue K562 cells were determined by RT-PCR analysis and western blot analysis, respectively. Cells transfected with a control siRNA construct served as negative controls. Samples are derived from the same experiment, and blots were processed in parallel. (C) An MTT assay was used to evaluate the effect of ND-09 on cell proliferation in wild-type, BCR-ABL knockdown, and BCR-ABL rescue cells. (D) Effect of ND-09 on apoptosis in BCR-ABL-depleted K562 cells. Values represent the average of three independent experiments. Data are presented as mean ± SEM (n=3). *P<0.05, **P<0.01 compared to the untreated control group. (E) The binding mode of ND-09 to BCR-ABL (PDB ID: 1IEP). a, ND-09 in the crystal structure of BCR-ABL with electrostatic coloring; b, Hydrogen bonds are depicted by dashed yellow lines; c, ND-09 in the crystal structure of BCR-ABL with hydrophobic coloring. (F) Effect of ND-09 on BCR-ABL kinase activity. Values represent the average of three independent experiments. Values are presented as mean ± SEM (n=3). (G) Levels of BCR-ABL, p-BCR-ABL, ABL, p-ABL, BCR, and p-BCR in K562 cells treated with ND-09 were examined by western blot analysis. Results were quantified by densitometric analysis of the bands and were normalized to GAPDH (internal control). Samples were derived from the same experiment, and blots were processed in parallel. Values represent the average of three independent experiments. Data are presented as the mean ± SEM (n=3). *P<0.05, **P<0.01 compared to the untreated control group.

    Techniques Used: Activity Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Western Blot, Transfection, Construct, Derivative Assay, MTT Assay, Binding Assay

    monoclonal antibodies against bcr abl  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc monoclonal antibodies against bcr abl
    Monoclonal Antibodies Against Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal antibodies against bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal antibodies against bcr abl - by Bioz Stars, 2023-01
    94/100 stars

    Images

    p rb 3908  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc p rb 3908
    P Rb 3908, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p rb 3908/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p rb 3908 - by Bioz Stars, 2023-01
    94/100 stars

    Images

    anti bcr/abl  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc anti bcr/abl
    Anti Bcr/Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti bcr/abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti bcr/abl - by Bioz Stars, 2023-01
    94/100 stars

    Images

    phospho bcr abl  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc phospho bcr abl
    Phospho Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phospho bcr abl - by Bioz Stars, 2023-01
    94/100 stars

    Images

    bcr abl  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc bcr abl
    The interaction between <t>BCR/ABL</t> and Beclin1. ( A ) Prediction of the interaction between Beclin1 and BCR/ABL using bioinformatics analysis. ( B ) Schematic structures of the Beclin1 mutant constructs, which were generated using a PCR-based mutagenesis method. ( C ) The BCR/ABL-binding motifs in Beclin1 were evaluated using Flag-Beclin1 and the deletion mutant constructs, which were cotransfected into HEK 293T cells with GST or GST-tagged BCR/ABL. The interactions between the proteins were determined via GST pull-down assays. ( D ) K562 cells electrotransfected with the indicated plasmids were subjected to immunoprecipitation with an anti- Flag antibody. The immunoprecipitated complexes were separated via SDS-PAGE and probed with an anti- Flag antibody to detect Flag-tagged Beclin1 and the mutant constructs and an anti-HA antibody to detect HA-tagged BCR/ABL. ( E ) K562-Beclin1 or K562-NC cells were electrotransfected with the pRL-TK and pGL3-BCR/ABL promoter constructs. The dual-luciferase reporter assay revealed the binding of Beclin1 to the BCR/ABL promoter in K562 cells. The results are presented as the mean ± standard deviation (SD); ** P <0.01. Data are representative of three independent experiments. Abbreviation: NC, negative control.
    Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bcr abl - by Bioz Stars, 2023-01
    94/100 stars

    Images

    1) Product Images from "The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy"

    Article Title: The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy

    Journal: Cancer Management and Research

    doi: 10.2147/CMAR.S202442

    The interaction between BCR/ABL and Beclin1. ( A ) Prediction of the interaction between Beclin1 and BCR/ABL using bioinformatics analysis. ( B ) Schematic structures of the Beclin1 mutant constructs, which were generated using a PCR-based mutagenesis method. ( C ) The BCR/ABL-binding motifs in Beclin1 were evaluated using Flag-Beclin1 and the deletion mutant constructs, which were cotransfected into HEK 293T cells with GST or GST-tagged BCR/ABL. The interactions between the proteins were determined via GST pull-down assays. ( D ) K562 cells electrotransfected with the indicated plasmids were subjected to immunoprecipitation with an anti- Flag antibody. The immunoprecipitated complexes were separated via SDS-PAGE and probed with an anti- Flag antibody to detect Flag-tagged Beclin1 and the mutant constructs and an anti-HA antibody to detect HA-tagged BCR/ABL. ( E ) K562-Beclin1 or K562-NC cells were electrotransfected with the pRL-TK and pGL3-BCR/ABL promoter constructs. The dual-luciferase reporter assay revealed the binding of Beclin1 to the BCR/ABL promoter in K562 cells. The results are presented as the mean ± standard deviation (SD); ** P <0.01. Data are representative of three independent experiments. Abbreviation: NC, negative control.
    Figure Legend Snippet: The interaction between BCR/ABL and Beclin1. ( A ) Prediction of the interaction between Beclin1 and BCR/ABL using bioinformatics analysis. ( B ) Schematic structures of the Beclin1 mutant constructs, which were generated using a PCR-based mutagenesis method. ( C ) The BCR/ABL-binding motifs in Beclin1 were evaluated using Flag-Beclin1 and the deletion mutant constructs, which were cotransfected into HEK 293T cells with GST or GST-tagged BCR/ABL. The interactions between the proteins were determined via GST pull-down assays. ( D ) K562 cells electrotransfected with the indicated plasmids were subjected to immunoprecipitation with an anti- Flag antibody. The immunoprecipitated complexes were separated via SDS-PAGE and probed with an anti- Flag antibody to detect Flag-tagged Beclin1 and the mutant constructs and an anti-HA antibody to detect HA-tagged BCR/ABL. ( E ) K562-Beclin1 or K562-NC cells were electrotransfected with the pRL-TK and pGL3-BCR/ABL promoter constructs. The dual-luciferase reporter assay revealed the binding of Beclin1 to the BCR/ABL promoter in K562 cells. The results are presented as the mean ± standard deviation (SD); ** P <0.01. Data are representative of three independent experiments. Abbreviation: NC, negative control.

    Techniques Used: Mutagenesis, Construct, Generated, Binding Assay, Immunoprecipitation, SDS Page, Luciferase, Reporter Assay, Standard Deviation, Negative Control

    Beclin1 overexpression in K562 cells induces BCR/ABL downregulation and promotes cell death via autophagic stimulation. ( A ) K562-NC or K562-Beclin1 cells were subjected to Western blot analysis to assess the levels of BCR/ABL, cleaved caspase-3 and cleaved PARP. The specific caspase-3 inhibitor DEVD was used to inhibit caspase-dependent apoptosis. ( B ) The indicated cells were cultured with or without the autophagy inhibitor 3-MA (5 mM) or the proteasomal inhibitor Epo (500 nM) for 24 h. Cell viability was measured using the CCK-8 assay. Data are presented as the mean ± SD of three independent experiments; * P <0.05, ** P <0.01. ( C ) Representative TEM photomicrographs of K562-Beclin1 and control K562 cells treated with 3-MA (5 mM) or Epo (500 nM) for 24 h and untreated cells. Arrows, autophagic vacuoles. Scale bars, 0.5 μm. ( D ) Western blot analysis of the levels of BCR/ABL and other autophagy-related proteins in K562-Beclin1 and K562-NC cells. Cells were pretreated in the absence or presence of 3-MA (5 mM) or Epo (500 nM) for 24 h. The results are representative of three independent experiments. Abbreviations: NC, negative control; 3-MA, 3-methyladenine; Epo, epoxomicin; DEVD, Z-DEVD-FMK.
    Figure Legend Snippet: Beclin1 overexpression in K562 cells induces BCR/ABL downregulation and promotes cell death via autophagic stimulation. ( A ) K562-NC or K562-Beclin1 cells were subjected to Western blot analysis to assess the levels of BCR/ABL, cleaved caspase-3 and cleaved PARP. The specific caspase-3 inhibitor DEVD was used to inhibit caspase-dependent apoptosis. ( B ) The indicated cells were cultured with or without the autophagy inhibitor 3-MA (5 mM) or the proteasomal inhibitor Epo (500 nM) for 24 h. Cell viability was measured using the CCK-8 assay. Data are presented as the mean ± SD of three independent experiments; * P <0.05, ** P <0.01. ( C ) Representative TEM photomicrographs of K562-Beclin1 and control K562 cells treated with 3-MA (5 mM) or Epo (500 nM) for 24 h and untreated cells. Arrows, autophagic vacuoles. Scale bars, 0.5 μm. ( D ) Western blot analysis of the levels of BCR/ABL and other autophagy-related proteins in K562-Beclin1 and K562-NC cells. Cells were pretreated in the absence or presence of 3-MA (5 mM) or Epo (500 nM) for 24 h. The results are representative of three independent experiments. Abbreviations: NC, negative control; 3-MA, 3-methyladenine; Epo, epoxomicin; DEVD, Z-DEVD-FMK.

    Techniques Used: Over Expression, Western Blot, Cell Culture, CCK-8 Assay, Negative Control

    Beclin1 overexpression-induced autophagy requires Atg7 and UVRAG in K562 cells and promotes BCR/ABL degradation via an interaction with p62/SQSTM1. ( A ) The knockdown efficiency of Atg7 or UVRAG by lentiviral vectors in K562 cells was determined via Western blotting. ( B ) The BCR/ABL and LC3-I/II expression levels in Atg7- and UVRAG-silenced K562 cells were assessed using Western blotting. ( C ) Fluorescence images showing p62/SQSTM1 (green) and BCR/ABL (red) in the indicated cells (K562-NC, K562-Beclin1, and K562-Beclin1 cells treated with 10 μM CA074 for 24 h). The nuclei were stained with DAPI (blue). The merged images show the colocalization of p62/SQSTM1 and BCR/ABL (yellow). All experiments were repeated at least three times. Abbreviations: NC, negative control; shRNA, short hairpin RNA.
    Figure Legend Snippet: Beclin1 overexpression-induced autophagy requires Atg7 and UVRAG in K562 cells and promotes BCR/ABL degradation via an interaction with p62/SQSTM1. ( A ) The knockdown efficiency of Atg7 or UVRAG by lentiviral vectors in K562 cells was determined via Western blotting. ( B ) The BCR/ABL and LC3-I/II expression levels in Atg7- and UVRAG-silenced K562 cells were assessed using Western blotting. ( C ) Fluorescence images showing p62/SQSTM1 (green) and BCR/ABL (red) in the indicated cells (K562-NC, K562-Beclin1, and K562-Beclin1 cells treated with 10 μM CA074 for 24 h). The nuclei were stained with DAPI (blue). The merged images show the colocalization of p62/SQSTM1 and BCR/ABL (yellow). All experiments were repeated at least three times. Abbreviations: NC, negative control; shRNA, short hairpin RNA.

    Techniques Used: Over Expression, Western Blot, Expressing, Fluorescence, Staining, Negative Control, shRNA

    Beclin1 overexpression in T315I mutant CML cells induces BCR/ABL downregulation and promotes autophagic cell death. ( A ) 32Dp210-T315I cells were cultured with different imatinib concentrations for 24 h, and the expression and activation of BCR/ABL protein were assessed via Western blotting. ( B ) Western blot analysis of BCR/ABL, p-BCR/ABL, Beclin1 and LC3-I/II levels in Beclin1-overexpressing or negative control 32Dp210-T315I cells. ( C ) CFC assays were performed with BMMCs derived from CML-BC patients with T315I mutant BCR/ABL. The primary cells were infected with LV-Beclin1 or LV-NC. After 14 days of culture in methylcellulose medium, GM-CFUs were observed. All experiments were repeated at least three times. Abbreviations: BMMCs, bone marrow mononuclear cells; NC, negative control; GM-CFUs, granulocyte-macrophage colony-forming units.
    Figure Legend Snippet: Beclin1 overexpression in T315I mutant CML cells induces BCR/ABL downregulation and promotes autophagic cell death. ( A ) 32Dp210-T315I cells were cultured with different imatinib concentrations for 24 h, and the expression and activation of BCR/ABL protein were assessed via Western blotting. ( B ) Western blot analysis of BCR/ABL, p-BCR/ABL, Beclin1 and LC3-I/II levels in Beclin1-overexpressing or negative control 32Dp210-T315I cells. ( C ) CFC assays were performed with BMMCs derived from CML-BC patients with T315I mutant BCR/ABL. The primary cells were infected with LV-Beclin1 or LV-NC. After 14 days of culture in methylcellulose medium, GM-CFUs were observed. All experiments were repeated at least three times. Abbreviations: BMMCs, bone marrow mononuclear cells; NC, negative control; GM-CFUs, granulocyte-macrophage colony-forming units.

    Techniques Used: Over Expression, Mutagenesis, Cell Culture, Expressing, Activation Assay, Western Blot, Negative Control, Derivative Assay, Infection

    Beclin1 overexpression downregulates BCR/ABL expression and induces autophagy in CML-LSCs. ( A ) Representative dot plots showing the purity of the CD34 + CD38 − LSCs collected via FACS from CML primary cells. ( B ) The CFC assay was performed with CML-LSCs infected with LV-Beclin1 or LV-NC. After 14 days of culture in methylcellulose medium, GM-CFUs were observed and counted (* P <0.05). ( C ) Western blot analysis of the expression levels of BCR/ABL and other autophagy-related proteins in CML-LSCs with and without Beclin1 overexpression. Three biological replicates were performed for each experiment. Abbreviations: NC, negative control; FITC, fluorescein isothiocyanate; PE, phycoerythrin; GM-CFUs, granulocyte-macrophage colony-forming units.
    Figure Legend Snippet: Beclin1 overexpression downregulates BCR/ABL expression and induces autophagy in CML-LSCs. ( A ) Representative dot plots showing the purity of the CD34 + CD38 − LSCs collected via FACS from CML primary cells. ( B ) The CFC assay was performed with CML-LSCs infected with LV-Beclin1 or LV-NC. After 14 days of culture in methylcellulose medium, GM-CFUs were observed and counted (* P <0.05). ( C ) Western blot analysis of the expression levels of BCR/ABL and other autophagy-related proteins in CML-LSCs with and without Beclin1 overexpression. Three biological replicates were performed for each experiment. Abbreviations: NC, negative control; FITC, fluorescein isothiocyanate; PE, phycoerythrin; GM-CFUs, granulocyte-macrophage colony-forming units.

    Techniques Used: Over Expression, Expressing, Infection, Western Blot, Negative Control

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Cell Signaling Technology Inc antibodies against bcr abl
    Antibodies Against Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies against bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    antibodies against bcr abl - by Bioz Stars, 2023-01
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc bcr abl 3908
    Bcr Abl 3908, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcr abl 3908/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bcr abl 3908 - by Bioz Stars, 2023-01
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti bcr abl antibody
    The expression of <t>BCR/ABL</t> protein in CML cells was decreased after Ab@Tf-Cou6-PLGA NPs treatment. a The expression of BCR/ABL and p-BCR/ABL in CML cells after Ab@Tf-Cou6-PLGA NPs treatment was detected by western blot assay. b The expression of p-STAT5, p-ERK and p-CRKL in CML cells was detected by western blot assay
    Anti Bcr Abl Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti bcr abl antibody/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti bcr abl antibody - by Bioz Stars, 2023-01
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc bcr abl
    The combination effects of CPT and <t>Bcr-Abl</t> tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of <t>cleaved</t> <t>caspase-3,</t> caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.
    Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bcr abl - by Bioz Stars, 2023-01
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc monoclonal antibodies against bcr abl
    The combination effects of CPT and <t>Bcr-Abl</t> tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of <t>cleaved</t> <t>caspase-3,</t> caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.
    Monoclonal Antibodies Against Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal antibodies against bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal antibodies against bcr abl - by Bioz Stars, 2023-01
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc p rb 3908
    The combination effects of CPT and <t>Bcr-Abl</t> tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of <t>cleaved</t> <t>caspase-3,</t> caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.
    P Rb 3908, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p rb 3908/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    p rb 3908 - by Bioz Stars, 2023-01
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc anti bcr/abl
    The combination effects of CPT and <t>Bcr-Abl</t> tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of <t>cleaved</t> <t>caspase-3,</t> caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.
    Anti Bcr/Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti bcr/abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti bcr/abl - by Bioz Stars, 2023-01
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc phospho bcr abl
    The combination effects of CPT and <t>Bcr-Abl</t> tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of <t>cleaved</t> <t>caspase-3,</t> caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.
    Phospho Bcr Abl, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho bcr abl/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phospho bcr abl - by Bioz Stars, 2023-01
    94/100 stars
      Buy from Supplier

    Image Search Results


    The expression of BCR/ABL protein in CML cells was decreased after Ab@Tf-Cou6-PLGA NPs treatment. a The expression of BCR/ABL and p-BCR/ABL in CML cells after Ab@Tf-Cou6-PLGA NPs treatment was detected by western blot assay. b The expression of p-STAT5, p-ERK and p-CRKL in CML cells was detected by western blot assay

    Journal: Journal of Hematology & Oncology

    Article Title: Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

    doi: 10.1186/s13045-021-01150-x

    Figure Lengend Snippet: The expression of BCR/ABL protein in CML cells was decreased after Ab@Tf-Cou6-PLGA NPs treatment. a The expression of BCR/ABL and p-BCR/ABL in CML cells after Ab@Tf-Cou6-PLGA NPs treatment was detected by western blot assay. b The expression of p-STAT5, p-ERK and p-CRKL in CML cells was detected by western blot assay

    Article Snippet: Proteins were detected by rabbit anti-BCR/ABL antibody (Cell Signaling Technology, USA) and rabbit anti-TRIM21 antibody (Abcam, USA).

    Techniques: Expressing, Western Blot

    The role of Trim-Away pathway in Ab@Tf-Cou6-PLGA NPs-mediated BCR/ABL degradation. a Proteasome inhibitor MG132 (100 nM) treatment weakened the BCR/ABL degradation effects of Ab@Tf-Cou6-PLGA NPs in CML cells. b The suppression effect of Ab@Tf-Cou6-PLGA NPs on BCR/ABL was reduced by TRIM21 knockdown. c Immunofluorescence assay was used to analyze the colocalization of BCR/ABL and TRIM21 after Ab@Tf-PLGA NPs treatment. Scale bar, 10 μm. d Co-IP analysis of the interaction of BCR/ABL and TRIM21 with Ab@Tf-Cou6-PLGA NPs treatment. e Co-IP analysis of the interaction of BCR/ABL and TRIM21 without Ab@Tf-Cou6-PLGA NPs treatment

    Journal: Journal of Hematology & Oncology

    Article Title: Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

    doi: 10.1186/s13045-021-01150-x

    Figure Lengend Snippet: The role of Trim-Away pathway in Ab@Tf-Cou6-PLGA NPs-mediated BCR/ABL degradation. a Proteasome inhibitor MG132 (100 nM) treatment weakened the BCR/ABL degradation effects of Ab@Tf-Cou6-PLGA NPs in CML cells. b The suppression effect of Ab@Tf-Cou6-PLGA NPs on BCR/ABL was reduced by TRIM21 knockdown. c Immunofluorescence assay was used to analyze the colocalization of BCR/ABL and TRIM21 after Ab@Tf-PLGA NPs treatment. Scale bar, 10 μm. d Co-IP analysis of the interaction of BCR/ABL and TRIM21 with Ab@Tf-Cou6-PLGA NPs treatment. e Co-IP analysis of the interaction of BCR/ABL and TRIM21 without Ab@Tf-Cou6-PLGA NPs treatment

    Article Snippet: Proteins were detected by rabbit anti-BCR/ABL antibody (Cell Signaling Technology, USA) and rabbit anti-TRIM21 antibody (Abcam, USA).

    Techniques: Immunofluorescence, Co-Immunoprecipitation Assay

    The oncogenesis of CML cells was impaired by Ab@Tf-Cou6-PLGA NPs in vivo. a Treatment schedule for CML mice model. b The maximum WBC counts of mice were recorded. c , d The weights of the liver and spleen of mice were measured. e The percent of CD45 + cells in the bone marrow of mice were detected by FCM. f Cells from bone marrow, liver, and spleen of mice were tested by Wright’s stain. The arrows indicate leukemic cells. Scale bar, 10 μm. g The expression of BCR/ABL was observed by immunofluorescence test. Scale bar, 10 μm. h The survival curves of mice were analyzed by Kaplan–Meier methods. Data are presented as the means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: Journal of Hematology & Oncology

    Article Title: Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

    doi: 10.1186/s13045-021-01150-x

    Figure Lengend Snippet: The oncogenesis of CML cells was impaired by Ab@Tf-Cou6-PLGA NPs in vivo. a Treatment schedule for CML mice model. b The maximum WBC counts of mice were recorded. c , d The weights of the liver and spleen of mice were measured. e The percent of CD45 + cells in the bone marrow of mice were detected by FCM. f Cells from bone marrow, liver, and spleen of mice were tested by Wright’s stain. The arrows indicate leukemic cells. Scale bar, 10 μm. g The expression of BCR/ABL was observed by immunofluorescence test. Scale bar, 10 μm. h The survival curves of mice were analyzed by Kaplan–Meier methods. Data are presented as the means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: Proteins were detected by rabbit anti-BCR/ABL antibody (Cell Signaling Technology, USA) and rabbit anti-TRIM21 antibody (Abcam, USA).

    Techniques: In Vivo, Staining, Expressing, Immunofluorescence

    Schematic diagram of degraded the BCR/ABL oncoprotein by Ab@Tf-Cou6-PLGA NPs. The anti-BCR/ABL antibodies were loaded into nanoparticles, and the transferrin was modified on the surface of Ab@Cou6-PLGA NPs to increase the CML targeting ability. The Ab@Tf-Cou6-PLGA NPs could deliver anti-BCR/ABL antibodies into CML cells. In the acidic environment of the lysosome of CML cells, the Ab@Tf-Cou6-PLGA NPs were degraded and the anti-BCR/ABL antibodies were released. The anti-BCR/ABL antibodies can specifically bind to the BCR/ABL oncoprotein and degrade the BCR/ABL protein via the Trim-Away pathway

    Journal: Journal of Hematology & Oncology

    Article Title: Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells

    doi: 10.1186/s13045-021-01150-x

    Figure Lengend Snippet: Schematic diagram of degraded the BCR/ABL oncoprotein by Ab@Tf-Cou6-PLGA NPs. The anti-BCR/ABL antibodies were loaded into nanoparticles, and the transferrin was modified on the surface of Ab@Cou6-PLGA NPs to increase the CML targeting ability. The Ab@Tf-Cou6-PLGA NPs could deliver anti-BCR/ABL antibodies into CML cells. In the acidic environment of the lysosome of CML cells, the Ab@Tf-Cou6-PLGA NPs were degraded and the anti-BCR/ABL antibodies were released. The anti-BCR/ABL antibodies can specifically bind to the BCR/ABL oncoprotein and degrade the BCR/ABL protein via the Trim-Away pathway

    Article Snippet: Proteins were detected by rabbit anti-BCR/ABL antibody (Cell Signaling Technology, USA) and rabbit anti-TRIM21 antibody (Abcam, USA).

    Techniques: Modification

    The combination effects of CPT and Bcr-Abl tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of cleaved caspase-3, caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.

    Journal: Pharmaceutical Biology

    Article Title: Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

    doi: 10.1080/13880209.2021.1944224

    Figure Lengend Snippet: The combination effects of CPT and Bcr-Abl tyrosine kinase inhibitors on cell viability and activities of crucial apoptosis mediators in K562-R cells. (A) Cell viability of K562-R cells was determined by MTT assay after the exposure of CPT and dasatinib for 48 h. (B) The effects of CPT and nilotinib on the cell viability of K562-R cells were measured by MTT assay. Data was represented as the mean ± SD obtained from three independent experiments. (C) Protein expression of cleaved caspase-3, caspase-9 and PARP after the treatment of CPT and three TKIs were analysed by western blot. (D) The semi-quantitative immunoblotting staining analysis of the indicated apoptosis related proteins by Image J. (E) The phosphorylation and total protein expression levels of Bcr-Abl, Src, STAT3 and eIF4E were determined after the combination treatment of CPT and imatinib, dasatinib and nilotinib in K562-R cells. (F) The indicated protein expression levels were quantified by Image J. Data were expressed as the mean ± SD, n = 3. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single TKI treatment group.

    Article Snippet: Antibodies used in this study were purchased from Cell Signalling Technology (MA, USA), including cleaved caspase-3 (#9664), cleaved PARP (#5625), p-STAT3 (#9145), Bcr-Abl (#3908), p-Bcr-Abl (#3009), p-Src (#2101) and β-Actin (#3700).

    Techniques: MTT Assay, Expressing, Western Blot, Staining

    CPT and imatinib treatment promoted the cleavages of caspase proteins and inhibited the expression levels of Bcr-Abl, p-STAT3 and p-eIF4E in tumour tissues. (A) Western blotting analysis on the expression levels of cleaved caspase-3, caspase-9 and PARP of tumour tissues from different groups. (B) Quantification of the cleaved caspase proteins by Image J. (C) Western blotting analysis on the expression levels of Bcr-Abl, p-STAT3 and p-eIF4E of tumour tissues from each group. (D) Quantification of the of the indicated crucial mediators in CML. The greyscale scans analysis of the western blot images was from three independent experiments and fold changes include the normalisation to β-actin. Data are represented as the mean ± SD. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single imatinib treatment group.

    Journal: Pharmaceutical Biology

    Article Title: Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia

    doi: 10.1080/13880209.2021.1944224

    Figure Lengend Snippet: CPT and imatinib treatment promoted the cleavages of caspase proteins and inhibited the expression levels of Bcr-Abl, p-STAT3 and p-eIF4E in tumour tissues. (A) Western blotting analysis on the expression levels of cleaved caspase-3, caspase-9 and PARP of tumour tissues from different groups. (B) Quantification of the cleaved caspase proteins by Image J. (C) Western blotting analysis on the expression levels of Bcr-Abl, p-STAT3 and p-eIF4E of tumour tissues from each group. (D) Quantification of the of the indicated crucial mediators in CML. The greyscale scans analysis of the western blot images was from three independent experiments and fold changes include the normalisation to β-actin. Data are represented as the mean ± SD. * p < 0.05, and ** p < 0.01 denote significant differences compared with the single imatinib treatment group.

    Article Snippet: Antibodies used in this study were purchased from Cell Signalling Technology (MA, USA), including cleaved caspase-3 (#9664), cleaved PARP (#5625), p-STAT3 (#9145), Bcr-Abl (#3908), p-Bcr-Abl (#3009), p-Src (#2101) and β-Actin (#3700).

    Techniques: Expressing, Western Blot